Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.

Saved in:
Bibliographic Details
Title: Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.
Authors: Labrada M; Center of Molecular Immunology, Vaccine Department, 216 St and 15th Ave., Atabey, Playa, P. O. Box 16040, Havana, 11600, Cuba. mayrel@cim.sld.cu, Clavell M, Bebelagua Y, León Jd, Alonso DF, Gabri MR, Veloso RC, Vérez V, Fernández LE
Source: Expert opinion on biological therapy [Expert Opin Biol Ther] 2010 Feb; Vol. 10 (2), pp. 153-62.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101125414 Publication Model: Print Cited Medium: Internet ISSN: 1744-7682 (Electronic) Linking ISSN: 14712598 NLM ISO Abbreviation: Expert Opin Biol Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1744-7682
DOI:10.1517/14712590903443084